Skip to main content
. 2008 Sep 22;5(5):285–291. doi: 10.7150/ijms.5.285

Table 5.

Non-Gemcitabine Regimens.

Study Treatment N Response Rate (%)
Romano et al62 Cisplatin + irinotecan 16 37%
Nehls et al.63 Capecitabine + Oxaliplatin 27 27%
Glover et al.64 Capecitabine + Oxaliplatin 21 19%
Sanz-Altamira65 Carboplatin + 5-FU/LV 14 21%